7Baggers
 AIM ImmunoTech Delays Q3 2025 Report Filing  TipRanks Mon, 17 Nov 2025 12:21:39 GMT
 published on: 2025-11-15 16:13:22  newser.com Sat, 15 Nov 2025 22:13:22 GMT
 12 Health Care Stocks Moving In Tuesday's After-Market Session  Benzinga Tue, 11 Nov 2025 21:07:32 GMT
 AIM ImmunoTech Details New UPMC Abstract on Completed  GlobeNewswire Mon, 10 Nov 2025 13:57:09 GMT
 {固定前缀} aim immunotech inc hxb stock analysis and forecast  earlytimes.in Thu, 06 Nov 2025 16:38:25 GMT
 aim immunotech to present phase 2 ovarian cancer study data at sitc  Investing.com India Wed, 05 Nov 2025 07:36:03 GMT
 aim immunotech to present phase 2 ovarian cancer study data at sitc by investing.com  Investing.com South Africa Tue, 04 Nov 2025 14:27:15 GMT
 aim immunotech announces european patent office grants  GlobeNewswire Mon, 03 Nov 2025 13:57:53 GMT
 aim immunotech presents at maxim growth summit 2025  MSN Sun, 02 Nov 2025 14:52:43 GMT
 AIM ImmunoTech Updates Certificate of Incorporation  TipRanks Wed, 29 Oct 2025 07:00:00 GMT
 bet on 5 top-ranked stocks with rising p/e  Zacks Investment Research Wed, 22 Oct 2025 16:31:22 GMT

AIM ImmunoTech Inc
(NYSE MKT:AIM) 

AIM stock logo

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for t...

Founded: 1966
Full Time Employees: 24
CEO: Thomas Kenwood Equels  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends